Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Urologic oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.urolonc.2013.01.007PMID 23562233
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

  2012influential reference
• Impact of C‐reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second‐line chemotherapy with gemcitabine, etoposide and cisplatin

  2012cited by this paper
• First- and second-line therapy for metastatic urothelial carcinoma of the bladder.

  2011cited by this paper
• Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).

  2009cited by this paper
• Combination chemotherapy of ifosfamide, 5‐fluorouracil, etoposide and cisplatin as perioperative treatment in lymph node positive bladder carcinoma patients treated by radical cystectomy

  2008cited by this paper
• Advanced bladder cancer: Status of first‐line chemotherapy and the search for active agents in the second‐line setting

  2008cited by this paper
• Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.

  2007cited by this paper
• Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

  2006cited by this paper
• Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma

  2006cited by this paper
• Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium

  2005cited by this paper
• Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

  2005cited by this paper
• Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience.

  2004cited by this paper
• Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

  2002cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Gemcitabine in bladder cancer.

  2000cited by this paper
• Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract

  2000cited by this paper
• Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.

  1999cited by this paper
• Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

  1999cited by this paper
• Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1997cited by this paper
• Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

  1994cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

  1990cited by this paper
• Should single agents be standard therapy for urothelial tract tumors?

  1989cited by this paper
• Cisplatin plus etoposide in small cell lung cancer.

  1988cited by this paper

• Efficacy and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: a preliminary report of real-world data from a single institution

  2024cites this paper
• Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma

  2020cites this paper
• Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma

  2019cites this paper
• Editorial Comment to Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes

  2016cites this paper
• Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery

  2015cites this paper
• [Current developments in the medical treatment of advanced urothelial carcinoma of the bladder].

  2014cites this paper
• Systemische Therapie des metastasierten Blasenkarzinoms

  2013cites this paper